The world’s first clinical trial on congenital deafness gene therapy showed that injecting a missing gene back into ear cells ...

The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...

Maker says Otarmeni will be offered for free in the U.S.

The US FDA has approved Otarmeni, a groundbreaking gene therapy by Regeneron, to restore natural hearing in children born ...

US FDA approves Regeneron’s gene therapy, Otarmeni for genetic hearing loss: Tarrytown, New York Regeneron Pharmaceuticals, Inc., a leadi ...

American drugmaker Regeneron's Otarmeni can restore natural hearing in children born deaf due to a genetic mutation ...

The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.

A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called ...

The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...

Envoy Medical Inc, a hearing health company pioneering fully implanted hearing solutions, announced that all 56 patients implanted and enrolled in its pivotal clinical trial evaluating the fully ...

Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...

In the largest and longest trial of its kind, 90% of patients receiving an experimental gene therapy for congenital deafness ...